Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive ms patients

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Adams, H. P.
  • Wagner, S.
  • Sobel, D. F.
  • Slivka, L. S.
  • Sipe, J. C.
  • Romine, J. S.
  • Beutler, Ernest
  • Koziol, James

publication date

  • 1999

journal

  • European Neurology  Journal

abstract

  • Cranial magnetic resonance imaging (MRI) is widely used to monitor disease activity in clinical trials in multiple sclerosis (MS). The purpose of this study is to examine lesion burden as determined from hypointense regions on postcontrast T1-weighted scans (or black holes), and lesion burden on conventional T2-weighted scans, from a cohort of secondary progressive MS patients who participated in a placebo-controlled, randomized, double-blind cross-over trial assessing the therapeutic efficacy of cladribine. T2 lesion volumes and black hole volumes are approximately normal distributed when log-transformed, and are highly correlated (adjusted R2 = 0.63). Changes in clinical scores could be predicted with a reasonable degree of precision from baseline scores and changes in T2 lesion volumes (adjusted R2 values 0.52-0.7). Stratification schemes for clinical trials should include the acute proportion of the disease (enhancing T1 lesions), degree of permanent damage (black holes), and T2 lesion volume.

subject areas

  • Adult
  • Cladribine
  • Disability Evaluation
  • Disease Progression
  • Double-Blind Method
  • Female
  • Humans
  • Immunosuppressive Agents
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis
  • Neurologic Examination
  • Placebos
  • Treatment Outcome
scroll to property group menus

Research

keywords

  • MR imaging
  • MS
  • clinical outcome
  • measures
  • multiple sclerosis
  • secondary progressive MS
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0014-3022

Digital Object Identifier (DOI)

  • 10.1159/000008069

PubMed ID

  • 10394049
scroll to property group menus

Additional Document Info

start page

  • 52

end page

  • 63

volume

  • 42

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support